Companies including Kneu Health and Rune Labs are raising money for Parkinson’s disease symptom monitoring tech.
There is a critical gap in communication about the potential of gene therapies, and it’s hurting parents of kids with rare diseases.
The deal, worth $4.7 billion upfront, centers on the drug efruxifermin, which has shown promising results in trials.
The therapy was abandoned by AstraZeneca, but a co-inventor believed the company had made a formula error in analyzing data.
The funding will be used to advance a drug for the lung condition COPD that was originally developed by Shanghai drugmaker Fosun Pharma.
Fundamental changes to pharma are destroying the model that let my nonprofit bring medicine to the Global South.
STAT reporters discuss the rebound in biotech stocks, Peter Marks' new job after leaving the FDA, and a math error by AstraZeneca.
With treatments for rare diseases, clinical data may not matter as much to FDA officials as they do in other cases.
